Quantcast

Latest Antivirals Stories

2014-04-14 12:35:09

Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver CongressTM 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon and ribavirin (followed by 12 or 36 weeks of peginterferon and ribavirin) was effective and well tolerated in hepatitis C virus (HCV) genotype 4-infected patients, consistent with previous observations in HCV genotype 1-infected patients. Overall, 65.4% of patients...

2014-04-14 12:05:11

High cure rates achieved with fixed-dose interferon-free and ribavirin-free regimen Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ledipasvir (LDV) 90mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection have been presented at the International Liver...

2014-04-14 11:03:19

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB). "Together these ground-breaking data will go a long way to influencing future CHB treatment guidelines," said EASL's Educational Councillor Professor Cihan Yurdaydin from the Department of Gastroenterology, University of...

Hepatitis C Treatment Without The Side Effects Of Interferon
2014-04-14 10:21:29

redOrbit Staff & Wire Reports - Your Universe Online A new orally-administered antiviral therapy has reportedly cured hepatitis C infection in over 90 percent of patients with liver cirrhosis, according to research published Saturday in the New England Journal of Medicine. Previously, the only treatment method that showed effectiveness against hepatitis C was interferon. However, patients treated with this agent often suffered relapses and experienced multiple adverse side effects....

2014-04-12 12:20:06

LONDON, April 12, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced new results from cohort 2 of the Phase 2 COSMOS study demonstrating that 93 percent of patients with the hepatitis C virus (HCV) and advanced liver fibrosis (METAVIR scores F3 and F4) who were treated with simeprevir administered once daily with Gilead Sciences, Inc.'s sofosbuvir for 12 weeks achieved sustained virologic response 12 weeks after the end of treatment (SVR12). The addition of...

2014-04-12 00:21:23

- In patients with compensated liver cirrhosis and genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, a difficult-to-treat population, TURQUOISE-II demonstrated SVR(12) rates of 91.8 and 95.9 percent after 12 and 24 weeks of treatment, respectively LONDON, April 12, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced that new, detailed results from its hepatitis C development program will be presented today at the International Liver Congress(TM) (ILC) 2014. Data from a pivotal phase...

2014-04-11 10:59:06

Scientists at The University of Texas at Austin have discovered that a protein produced by the influenza A virus helps it outwit one of our body's natural defense mechanisms. That makes the protein a potentially good target for antiviral drugs directed against the influenza A virus. Better antiviral drugs could help the millions of people annually infected by flu, which kills up to 500,000 people each year. When an influenza virus infects a human cell, it uses some of the host's...

2014-04-11 00:21:52

-SVR(12) rates of 96 percent were achieved in both SAPPHIRE-I (new to therapy) and SAPPHIRE-II (treatment-experienced with pegylated interferon and ribavirin) in adult patients with genotype 1 chronic hepatitis C virus infection LONDON, April 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that detailed results from its phase III pivotal study, SAPPHIRE-I, will be presented today at the International Liver Congress(TM) (ILC) 2014 and featured in the ILC press conference....

2014-04-02 08:33:17

MOSCOW, April 2, 2014 /PRNewswire/ -- Hepatera Ltd. [http://www.hepatera.ru/?ln=en ] announces initiation of a clinical trial investigating Myrcludex B in chronically HBV infected patients who are also infected with hepatitis delta virus (HDV). Hepatera is financed by Maxwell Biotech Venture Fund [http://www.maxwellbiotech.com ] formed with the participation of RVC [http://www.rusventure.ru/en ] - Russia's government fund of venture capital funds. Hepatera was...

2014-04-02 08:32:34

OPTIMIST represents the first Phase 3 studies of the two treatments in a regimen without interferon and ribavirin CORK, Ireland, April 2, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related